Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
The cardiovascular disease, pulmonary arterial hypertension, affects around 6,500 people in the UK
Read More
Tag: Pulmonary Arterial Hypertension
Chiesi and Gossamer collaborate to develop drug to treat respiratory diseases
Gossamer’s seralutinib is designed to treat pulmonary arterial hypertension and other indications
Read More
United Theraputics ends esuberaprost trial early
The company kept the announcement short, but said the study did not meet its primary endpoint.
Read More
NHS England to fund Actelion’s Uptravi
Actelion Pharmaceuticals has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH), can now be treated with Uptravi.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
